• Ic Caggiano Sa
• Ic Caggiano.gov

The insulinlike growth factor 1 receptor (IGF-1R) is a new target for the treatment of breast cancer. Patients with breast cancer lesions that express IGF-1R may benefit from treatment with anti–IGF-1R antibodies. Therefore, the aim of the present study was to develop a noninvasive, in vivo imaging method, using radiolabeled antibodies, to visualize IGF-1R expression. Microwave IC Packaging Selected Publications 'Electrical Characterization and Modeling of IC Packaging,' Charles Harper, Editor, Packaging and Interconnect Handbook, McGraw Hill, February, 2000. There are 4 ways to get from Salerno to Caggiano by train, bus, night bus, taxi or car. Select an option below to see step-by-step directions and to compare ticket prices and travel times in.

With high ex­pec­ta­tions on Provenge, Den­dreon is 'sol­d' (again) in $832M deal

Den­dreon — and its fad­ed can­cer star Provenge — is chang­ing hands for the sec­ond time in less than two years.

Their new own­er is Nan­jing Xin­bai, a de­part­ment store con­glom­er­ate that’s been beef­ing up its phar­ma­ceu­ti­cal busi­ness, which first pro­posed to snap up the prostate can­cer cell ther­a­py last No­vem­ber.

The deal is val­ued at $872 mil­lion (CNY 59,680,000,000), though no cash is in­volved. San­pow­er Group, which cur­rent­ly owns Den­dreon through a Hong Kong-based sub­sidiary called Shid­ing Sheng­wu Biotech­nol­o­gy, is al­so a con­trol­ling stock­hold­er of Xin­bai. Mov­ing Den­dreon in­to pub­licly trad­ed Xin­bai “has been San­pow­er’s long-term plan since ac­quir­ing Den­dreon in 2017,” Den­dreon CEO Jim Caggiano wrote via email.

In ex­change for pass­ing off Shid­ing, San­pow­er’s get­ting 180 mil­lion more of Xin­bai’s shares, boost­ing its hold­ing from 33.1% to 42.43%.

These are ex­pen­sive shares. San­pow­er is ef­fec­tive­ly bet­ting $511 mil­lion on Den­dreon’s fu­ture earn­ing po­ten­tial by pay­ing a 60% pre­mi­um over Xin­bai’s cur­rent stock price. And that’s af­ter pay­ing $820 mil­lion in cash to nab the com­pa­ny from Valeant in the first place.

“San­pow­er sac­ri­ficed CNY3.5 bil­lion of its own in­ter­est to in­fuse Den­dreon in­to Nan­jing Xin­bai as promised,” Guikan Hua, San­pow­er vice pres­i­dent and spokesper­son, toldThe Pa­per, “show­ing the stock­er­hold­ers’ full sup­port and op­ti­mism to­ward Nan­jing Xin­bai.”

That lev­el of con­fi­dence would fit with the im­pres­sion I got from Caggiano, who told me late last year — be­fore Xin­bai would an­nounce its in­ten­tions to buy the com­pa­ny — that San­pow­er “has proven to be a great part­ner” who’s very hands off in the US while lead­ing the charge to bring Provenge to Hong Kong and main­land Chi­na.

Ac­cord­ing to him, there will be no changes to struc­ture, strat­e­gy or per­son­nel at the com­pa­ny af­ter the change of own­er­ship.

Ic Caggiano Sa

Ic Caggiano.gov

Cur­rent­ly ap­proved in the US, Provenge is an au­tol­o­gous cell ther­a­py that re­quires a quick turn­around in the man­u­fac­tur­ing process. With help from San­pow­er, Seal Beach, CA-based Den­dreon has pur­chased an im­munother­a­py man­u­fac­tur­ing fa­cil­i­ty in Hong Kong with goals of fil­ing an NDA in the re­gion soon.